CGBio (CEO Hyun-Seung Yu), a leading bio-regeneration medical company, successfully concluded its ‘Meet the Master’ global seminar targeting Indonesian orthopedic professionals, as announced on the 28th.
CGBio organizes the ‘Meet the Master’ global seminar by specialization. Specifically for bone substitutes and implants, the seminar is divided into spine and trauma topics. The seminar is held at least twice a year aiming to enhance the understanding and knowledge level of global medical professionals.
Compared to countries like Europe and the USA, Indonesia has a relatively low utilization of bone substitutes loaded with bone morphogenetic protein (rhBMP-2) for bone defects and trauma treatments. CGBio aims to introduce new methods of using bone substitutes and enhance the knowledge level of local medical professionals, ultimately improving the quality of life for Indonesian patients with bone defects.
The recent ‘Meet the Master’ was held sequentially in three major Indonesian regions – Jakarta, Surabaya, and Bali – from August 12 to 15, attended by 115 orthopedic specialists from all over Indonesia.
The seminar, led by Professor Jong-Keon Oh from Korea University Guro Hospital, centered on the theme, “How rhBMP-2 with HA carriers transforms my approach in Orthopedic Trauma, spanning from bone defects to intricate fractures.”
Especially in Bali, the last event location, medical professionals from Indonesia, Thailand, Vietnam, Singapore, and Malaysia discussed and debated the latest insights in the bone substitute field and real-life applications of bone substitute ‘NOVOSIS’ loaded with rhBMP-2.
Professor Ismail Hadisoebroto Dilogo of Cipto Mangunkusumo Hospital said, “For bone fusion, a concept called the ‘Diamond Concept’ requires four essential elements (cells, growth factors, scaffolds, and mechanical fixation). NOVOSIS has both a scaffold and a growth factor.” He further explained that “rhBMP-2, the most potent bone growth factor currently available, can expedite recovery when used in surgeries for hip fractures and non-unions.”
Medical professionals noted that NOVOSIS is more efficient and stable for bone regeneration than the widely used collagen sponge-based bone substitutes. Professor Jong-Keon Oh stated that “NOVOSIS uses a hydroxyapatite carrier, which slowly releases bone morphogenetic protein, significantly reducing the risk of excessive bone formation, making its use much more stable.”
Following this event, CGBIO plans to collaborate with medical professionals from Indonesia and Korea for joint research, establish ties with reputable universities for future product development, and strengthen local business with an open collaboration strategy. They also plan to expand into the broader Asian market through active licensing and global marketing.
Hyun-Seung Yu, the Chief Executive of CGBIO, remarked, “The ‘Meet the Master’ seminar served as a significant moment for us to reaffirm how advancements in orthopedic medical devices enhance patient results. Observing global use cases of our bone substitute products was particularly impactful.” He further stated, “We’re committed to organizing more ‘Meet the Master’ sessions, diligently gathering feedback from experts, and spearheading advancements in the treatment landscape of orthopedic trauma, from bone defects to intricate fractures.”
▲ Attendees are listening to ‘Meet the Master’ seminar session held in Bali, Indonesia
▲ Professor Jong-Keon Oh from Korea University Guro Hospital is giving a presentation
